15038 studies
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)-central to type 2 diabetes mellitus (T2DM) management owing to their comprehensive benefits (glycemic control, weight reduction, cardiovascular benefits, and renal protection)-exhibit a concerning…
STUDY QUESTION: What is the association between periconceptional GLP-1 receptor agonist exposure and risk of obstetric complications? SUMMARY ANSWER: Periconceptional GLP-1 receptor agonist exposure was associated with increased preterm birth risk wh…
BACKGROUND: Incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1Ras), dual GLP-1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits. However, their impact on skeletal muscle mitochondrial…
Metabolic dysfunction-associated steatotic liver disease (MASLD), a leading global cause of chronic liver disease, encompasses a wide spectrum of disease stages from isolated hepatic steatosis to cirrhosis. After decades of limited therapeutic option…
Semaglutide has emerged as a leading therapy for metabolic disorders, with robust evidence supporting its role in treating obesity and type 2 diabetes while reducing cardiovascular and renal risks. However, limited data exist on the proportion of pat…
INTRODUCTION: Diabetes mellitus is the leading global cause of chronic kidney disease (CKD) and end-stage renal disease. Although cardiovascular outcomes have improved substantially, renal risk remains high. Glucagon-like peptide 1 (GLP-1) receptor a…
INTRODUCTION: The aim of this study was to evaluate changes in clinical parameters among adults with type 2 diabetes (T2D) after initiating subcutaneous semaglutide in Chinese clinical practice. METHODS: SCHOLAR was a retrospective cohort study using…
Background Saudi Arabia has one of the highest global prevalences of diabetes mellitus (39.5%), with cardiovascular disease (CVD) representing the leading cause of mortality among patients with diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibi…
OBJECTIVES: We reviewed weight loss and gaining wrinkles, and the impact of weight loss drugs on facial aesthetics. METHODS: The resources from Eskişehir Osmangazi and Kirikkale Universities, along with Google, Google Scholar, PubMed, EBSCO, and ProQ…
OBJECTIVES: To evaluate the quality, reliability, and thematic content of user-generated videos on TikTok concerning glucagon-like peptide-1 (GLP-1) receptor agonists. METHODS: This cross-sectional study analyzed the top 400 most popular videos using…
BACKGROUND: A knowledge gap remains in how the rate of body weight reduction impacts efficacy and safety of obesity management medications. This SURMOUNT-5 post hoc analysis aimed to define rapid responders and evaluated efficacy and safety of tirzep…
BACKGROUND: Evidence, including animal, clinical, and real-world studies in individuals with type 2 diabetes and/or obesity, suggests reduced risk of dementia and Alzheimer's disease after GLP-1 receptor agonist exposure. The evoke and evoke+ trials…
Metabolic dysfunction-associated steatotic liver disease (MASLD) has rapidly emerged as the leading cause of chronic liver disease worldwide, gradually replacing viral hepatitis in clinical and epidemiological relevance. Italian data mirror global tr…
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia in elderly people, marked by the accumulation of amyloid-β plaques and neurofibrillary tangles, resulting in neurodegeneration and cognitive declin…
Background and AimEmerging evidence suggests that weight loss associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be in part attributable to changes in lean mass, which has potential clinical implications. This study evaluates t…